Stock Events

Xeris Biopharma 

$2.45
48
+$0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.16
-0.11
-0.05
0
Expected EPS
-0.12
Actual EPS
-0.14

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A8E.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mannkind
MNKD
Mkt Cap1.55B
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, competing directly with Xeris's inhaled and injectable therapies.
Novo Nordisk
NVO
Mkt Cap481.67B
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care, providing products that compete in the diabetes therapeutic area with Xeris.
Sanofi
SNY
Mkt Cap130B
Sanofi is a global life sciences company that offers a range of diabetes solutions, including insulin therapies that compete with Xeris's glucagon rescue pen.
Lilly(Eli) &
LLY
Mkt Cap901.36B
Eli Lilly and Company is a global healthcare leader that manufactures medicines for diabetes care, directly competing with Xeris's diabetes management products.
Astrazeneca
AZN
Mkt Cap245.69B
AstraZeneca operates in the biopharmaceutical sector, focusing on the development of new medicines for chronic diseases, including diabetes, thus competing with Xeris.
Merck &
MRK
Mkt Cap323.59B
Merck & Co., Inc. offers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, including treatments for diabetes, making it a competitor.
Bristol-Myers Squibb
BMY
Mkt Cap82.02B
Bristol Myers Squibb is a global biopharmaceutical company whose portfolio of medicines includes treatments for diabetes and cardiovascular diseases, areas where Xeris also operates.
Pfizer
PFE
Mkt Cap163.88B
Pfizer Inc. is a research-based global biopharmaceutical company with a broad range of products in various therapeutic areas, including those competing with Xeris's offerings.
Tandem Diabetes Care
TNDM
Mkt Cap2.98B
Tandem Diabetes Care, Inc. designs, develops, and commercializes products for people with insulin-dependent diabetes, directly competing with Xeris's diabetes management solutions.
Insulet
PODD
Mkt Cap14.15B
Insulet Corporation is an innovative medical device company focused on making the lives of people with diabetes easier through its Omnipod Insulin Management System, competing in the diabetes care market with Xeris.

About

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Show more...
CEO
Mr. Paul R. Edick
Employees
294
Country
United States
ISIN
US98422E1038
WKN
000A3C4ZC

Listings